Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comprehensive Assessment of Erenumab Efficacy in High Frequency Episodic Migraine
2019-003646-33Phase 4Completed
- Sponsor
- Amgen
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing Erenumab with Placebo (2 arms). Primary endpoint: Change from baseline in mean monthly hours of at least moderate headache pain intensity over months 1, 2, and 3. Started Mar 2020; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on 2019-003646-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003646-33.